Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 11Osteoporosis 5Prostatic Neoplasms 4Neoplasms 4Multiple Myeloma 2Unspecified Childhood Solid Tumor, Protocol Specific 1Testicular Neoplasms 1Smoldering Multiple Myeloma 1Regional Osteoporosis as a Result of Chemotherapy 1Recurrence 1Polycystic Ovary Syndrome 1Paraganglioma, Extra-Adrenal 1Pain 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Metabolic Syndrome 1Menstruation Disturbances 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphedema 1Leukemia 1Hodgkin Disease 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Depression 1Cicatrix 1Cardiovascular Diseases 1Carcinoma, Transitional Cell 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × Absorptiometry, Photon × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT00401011 2018-02-23

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

AEterna Zentaris

Phase 1/2 Completed
84 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡